Blood Letting in High-Ferritin Type 2 Diabetes
- 1 April 2002
- journal article
- clinical trial
- Published by American Diabetes Association in Diabetes
- Vol. 51 (4), 1000-1004
- https://doi.org/10.2337/diabetes.51.4.1000
Abstract
Iron-related insulin-resistance is improved by iron depletion or treatment with iron chelators. The aim of this study was to evaluate insulin sensitivity and insulin secretion after blood letting in patients who had high-ferritin type 2 diabetes and were randomized to blood letting (three phlebotomies [500 ml of blood] at 2-week intervals, group 1) or to observation (group 2). Insulin secretion and sensitivity were tested at baseline and 4 and 12 months thereafter. The two groups were matched for age, BMI, pharmacologic treatment, and chronic diabetic complications. All patients were negative for C282Y mutation of hereditary hemochromatosis. Baseline glycated hemoglobin (6.27 ± 0.9% vs. 6.39 ± 1.2%), insulin sensitivity (2.75 ± 1.8 vs. 3.2 ± 2.1 mg · dl−1 · min−1), and area under the curve for C-peptide (AUCC-peptide; 38.7 ± 11.6 vs. 37.6 ± 14.1 ng · ml−1 · min−1) were not significantly different between the two groups of patients. Body weight, blood pressure, blood hematocrit levels, and drug treatment remained essentially unchanged during the study period. As expected, serum ferritin, transferrin saturation index, and blood hemoglobin decreased significantly at 4 months only in patients who received blood letting. In parallel to this changes, blood HbA1c decreased significantly only in group 1 subjects (mean differences, −0.61; 95% CI, −0.17 to −1.048; P = 0.01). AUCC-peptide decreased by −10.2 ± 6.3% after blood letting. In contrast, a 10.4 ± 6.4% increase in AUCC-peptide was noted in group 2 subjects at 4 months (P = 0.032). At 12 months, AUCC-peptide returned to values not significantly different from baseline in the two groups of subjects. At 4 months, the change in insulin sensitivity from baseline was significantly different between the two groups (80.6 ± 43.2% vs. −8.6 ± 9.9% in groups 1 and 2, respectively, P = 0.049). At 12 months, the differences between the two groups were even more marked (55.5 ± 24.8% vs. −26.8 ± 9.9%; P = 0.005). When the analysis was restricted to those subjects who completed the follow-up until 12 months, results did not show differences compared with the changes observed at 4 months, except for insulin sensitivity. A statistically significant increase in insulin sensitivity was observed in the blood-letting group (from 2.30 ± 1.81 to 3.08 ± 2.55 mg · dl−1 · min−1 at 4 months, to 3.16 ± 1.85 mg · dl−1 · min−1 at 12 months; P = 0,045) in contrast with group 2 subjects (from 3.24 ± 1.9 to 3.26 ± 2.05 mg · dl−1 · min−1 at 4 months, to 2.31 ± 1.35 mg · dl−1 · min−1 at 12 months). In summary, blood letting led simultaneously to decreased blood HbA1c levels and to changes in insulin secretion and insulin resistance that were significantly different from those observed in a matched observational group of subjects with high-ferritin type 2 diabetes. The mechanisms for improvement in peripheral insulin sensitivity after blood letting should be investigated further.Keywords
This publication has 32 references indexed in Scilit:
- The role of oxidative stress in the onset and progression of diabetes and its complications: asummary of a Congress Series sponsored byUNESCO-MCBN, the American Diabetes Association and the German Diabetes SocietyDiabetes/Metabolism Research and Reviews, 2001
- C282Y and H63D mutations of the hemochromatosis candidate gene in type 2 diabetes.Diabetes Care, 1999
- Transition Metals Bind to Glycated Proteins Forming Redox Active “Glycochelates”: Implications for the Pathogenesis of Certain Diabetic ComplicationsBiochemical and Biophysical Research Communications, 1998
- Body Iron Stores Are Associated With Serum Insulin and Blood Glucose Concentrations: Population study in 1,013 eastern Finnish menDiabetes Care, 1997
- Factors determining glucose tolerance in patients with thalassemia majorJournal of Clinical Endocrinology & Metabolism, 1993
- No effect of deferoxamine therapy on glucose homeostasis and insulin secretion in individuals with NIDDM and elevated serum ferritinDiabetes, 1993
- Protein glycation and oxidative stress in diabetes mellitus and ageingFree Radical Biology & Medicine, 1991
- Deferoxamine therapy in high-ferritin diabetesDiabetes, 1989
- Insulin Resistance and Hyperinsulinemia in Patients with Thalassemia Major Treated by HypertransfusionNew England Journal of Medicine, 1988
- The haemochromatotic human pancreas: a quantitative immunohistochemical and ultrastructural studyDiabetologia, 1987